|Articles|February 1, 2001
- Pharmaceutical Executive-12-01-2001
- Volume 0
- Issue 0
Generics Debate Escalates
Calls for change reflect that generic products are a therapeutic mainstay and that patients and providers want earlier access to inexpensive medicines.
Advertisement
Articles in this issue
about 24 years ago
States Target DTC Advertisingabout 24 years ago
Transparent Momentabout 24 years ago
IFPMA Disputes Doctors Without Boarders Reportabout 24 years ago
GSK at Odds with Activistsabout 24 years ago
Protecting People Everywhereabout 24 years ago
Opening the Door to Japanabout 24 years ago
Trade Pact Weakens Patent Protectionsabout 24 years ago
EC Questions Dual Pricingabout 24 years ago
Genetic Test Results Off Limits-For Nowabout 24 years ago
Precious PlasmaNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
2
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
3
Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER
4
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
5
